Deletion of TET2 substantially reduced the activity of vitamin C to facilitate the survival of RCC cell-bearing mice after injection with anti-PD-L1, suggesting that TET2 is the major target of vitamin C in boosting the antitumor immunity and efficacy of anti-PD-L1 therapy. The gene discussed is TET2; the disease is renal cell carcinoma.